TY - JOUR
T1 - Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care
AU - Stefanutti, C.
AU - Vivenzio, A.
AU - Di Giacomo, S.
AU - Di Giacomo, Salvatore
AU - Mazzarella, B.
AU - Ferraro, Pietro Manuel
AU - Abbolito, S.
PY - 2010
Y1 - 2010
N2 - Background/aims: To assess LDL-apheresis efficacy to lower Lp(a) and to compare the effects of Usual Medical Care (UMC) a 12-months study was carried out. The incidence of new coronary artery disease (CAD) events/need of revascularization, was also monitored. Methods: Twenty-one patients with hyperLp(a)lipidemia and angiographically documented CAD were randomly assigned to LDL-apheresis every week, or the UMC. Results: LDL-apheresis group, averaged an Lp(a) reduction of 57.8 ± 9.5% vs. basal values (P < 0.001). In the UMC group Lp(a) increased in 1 year to 14.7 ± 36.5% (P = 0.66). Stepwise multivariate regression analysis for predictors of Lp(a) including: type of treatment, smoking, hypertension, age, age at first cardiovascular event, initial Lp(a), LDL, and BMI values, was performed. Only the type of treatment was co-related (P < 0.001): Lp(a) variation (beta) = 0.863. The model has R2 adjusted relative risk of 0.725. Conclusion: LDL-apheresis could be the first line treatment of isolated hyperLp(a)lipidemia when CAD is established. New CAD events/cardiac interventions were not observed. © 2009 Elsevier Ltd. All rights reserved.
AB - Background/aims: To assess LDL-apheresis efficacy to lower Lp(a) and to compare the effects of Usual Medical Care (UMC) a 12-months study was carried out. The incidence of new coronary artery disease (CAD) events/need of revascularization, was also monitored. Methods: Twenty-one patients with hyperLp(a)lipidemia and angiographically documented CAD were randomly assigned to LDL-apheresis every week, or the UMC. Results: LDL-apheresis group, averaged an Lp(a) reduction of 57.8 ± 9.5% vs. basal values (P < 0.001). In the UMC group Lp(a) increased in 1 year to 14.7 ± 36.5% (P = 0.66). Stepwise multivariate regression analysis for predictors of Lp(a) including: type of treatment, smoking, hypertension, age, age at first cardiovascular event, initial Lp(a), LDL, and BMI values, was performed. Only the type of treatment was co-related (P < 0.001): Lp(a) variation (beta) = 0.863. The model has R2 adjusted relative risk of 0.725. Conclusion: LDL-apheresis could be the first line treatment of isolated hyperLp(a)lipidemia when CAD is established. New CAD events/cardiac interventions were not observed. © 2009 Elsevier Ltd. All rights reserved.
KW - Acrylic Resins
KW - Adult
KW - Aged
KW - Anticholesteremic Agents
KW - Blood Component Removal
KW - Chromatography, Affinity
KW - Coronary Angiography
KW - Coronary Artery Disease
KW - Coronary angiography
KW - Coronary artery disease
KW - Diet, Fat-Restricted
KW - Exercise Therapy
KW - Female
KW - Follow-Up Studies
KW - Hematology
KW - Humans
KW - HyperLp(a)lipoproteinemia
KW - Hyperlipoproteinemias
KW - Incidence
KW - LDL-apheresis
KW - Lipoprotein(a)
KW - Male
KW - Middle Aged
KW - Myocardial Revascularization
KW - Risk
KW - Treatment Outcome
KW - Acrylic Resins
KW - Adult
KW - Aged
KW - Anticholesteremic Agents
KW - Blood Component Removal
KW - Chromatography, Affinity
KW - Coronary Angiography
KW - Coronary Artery Disease
KW - Coronary angiography
KW - Coronary artery disease
KW - Diet, Fat-Restricted
KW - Exercise Therapy
KW - Female
KW - Follow-Up Studies
KW - Hematology
KW - Humans
KW - HyperLp(a)lipoproteinemia
KW - Hyperlipoproteinemias
KW - Incidence
KW - LDL-apheresis
KW - Lipoprotein(a)
KW - Male
KW - Middle Aged
KW - Myocardial Revascularization
KW - Risk
KW - Treatment Outcome
UR - http://hdl.handle.net/10807/93226
U2 - 10.1016/j.transci.2009.10.003
DO - 10.1016/j.transci.2009.10.003
M3 - Article
SN - 1473-0502
VL - 42
SP - 21
EP - 26
JO - Transfusion and Apheresis Science
JF - Transfusion and Apheresis Science
ER -